Foundation for Innovative New Diagnostics Find
Public records show a registered, tax-exempt organization in good standing.
What it says it does
FIND IS AN INTERNATIONAL NON-PROFIT ORGANIZATION THAT ENABLES THE DEVELOPMENT AND DELIVERY OF MUCH-NEEDED DIAGNOSTIC TESTS FOR POVERTY-RELATED DISEASES. FIND ACTS AS A BRIDGE BETWEEN EXPERTS IN TECHNOLOGY DEVELOPMENT, POLICY AND CLINICAL CARE, REDUCING BARRIERS TO INNOVATION AND EFFECTIVE IMPLEMENTATION OF DIAGNOSTIC SOLUTIONS IN LOW-AND-MIDDLE-INCOME COUNTRIES.
- Income
- $49.3 million
- Spending
- $56.8 million
- Spent on programs
- 81%
- Reserves
- 1.4 months of spending
- Largest source of income
- donations and private grants, 54%
- Employees
- 227
- Volunteers
- 3
- Highest pay
- $414,021, deputy director, finance (thru 11/24)
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Weak: 27 out of 100. Higher than 2% of charities in its peer group (medical research, $10m to $100m).
Reserves
10 of 35Spendable reserves would cover 1.4 months of spending.
Debt
2 of 20It owes 83% of what it owns.
Living within its means
0 of 15Spending exceeded income by 15% of income.
Income trend
0 of 15Income fell 46% on the year before.
Spending floor
15 of 1581% of spending went to programs and raising each dollar of donations cost 1 cents.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 90 out of 100. Higher than 28% of charities in its peer group (medical research, $10m to $100m).
Independent board
25 of 259 of 9 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
0 of 10Did not give the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (5)
- $13.9 million spent. (EXPENSES $13,927,035 INCLUDING GRANTS OF $6,601,315)(REVENUE $0) In 2024, FIND's Technology & Development Department continued to advance global health through innovative diagnostics, focusing on expanding access, digital transformation, and the development of next-generation solutions. The department's activities were aligned with FIND's mission to improve health outcomes in low- and middle-income countries (LMICs) by accelerating the availability and adoption of high-quality diagnostic tools. Accelerate access to SARSCOV-2 AgRDTs for Professional Use with manufacturing expansion: FIND supported access to COVID-19 antigen rapid diagnostic tests (AgRDTs) in resource-limited countries by fostering regional manufacturing partnerships. In 2024, the focus was on transferring HIV test technology and building manufacturing capacity with African-based manufacturers, strengthening local production and sustainability. These efforts aimed to ensure a resilient supply chain and reduce dependency on imports. Point Of Care Molecular Diagnostic (POC MDx): FIND invested in four innovative technologies to deliver true and near point-of-care solutions for respiratory panel testing. These platforms were designed to provide rapid, accurate diagnostics at the community level, enabling timely treatment and improved patient outcomes in LMICs. In addition, FIND has conducted an in-depth investigation and assessment of true-POC MDx that led to the launch of feasibility studies on seven small, portable, innovative POC molecular devices. COVID-19 Digital Validation Platform: Building on previous work in computer-aided detection (CAD) for tuberculosis, FIND evaluated digital diagnostics for COVID-19, positioning itself as a leader in digital diagnostic evaluation for the global health community. Technology landscape and DxConnect Test Directory: A core enabler of FIND impact is its ability to generate and disseminate high-quality, open-access IVD technology data that informs decision-making across the diagnostic ecosystem. Our DxConnect Test Directory provides competitive intelligence and detailed information on diagnostic tests and platforms that improve transparency, supports procurement planning, and facilitate innovation. This resource is increasingly used by donors, implementers, and manufacturers to guide strategic investments and product development. FIND has conducted more than 20 technology landscapes covering areas such as antimicrobial resistance, neglected tropical diseases, outbreaks, women's health, and non-communicable diseases. Seq&Treat: FIND accelerated the introduction and adoption of commercial targeted sequencing for the diagnosis of drug-resistant TB (DR-TB). Key 2024 achievements included clinical trials in India, South Africa, and Georgia to support WHO guidance; establishment of a WHO clinical knowledge base (TB-KB) for global sequencing data; proof-of-principle delivery models in India, Indonesia, South Africa, and Brazil; and efforts to address access barriers through pricing collaboration, market mapping, and knowledge sharing. Supporting the development, implementation and evaluation of integrated digital screening tools, and systems for routine collection of syndromic data, at the community level in Rwanda and Kenya: FIND developed and evaluated digital screening approaches at the community level. By integrating disease screening into digital platforms and enhancing contact tracing modules for tuberculosis, FIND demonstrated the feasibility of decentralized community-level screening in Rwanda and Kenya. Shaping the Global Agenda for Genomics: FIND contributed to shaping the global genomics agenda by mapping pathogen genomic sequencing investments and identifying gaps and opportunities for strategic collaboration. This work informed global stakeholders and supported the development of coordinated genomic surveillance strategiesGenomics Costing Tool: FIND co-developed and piloted the Genomics Costing Tool (GCT), a resource to support governments and partners in planning and budgeting for genomic sequencing in public health. In 2024, FIND collaborated with WHO and country partners to validate the tool using tuberculosis genomic sequencing as a use case. The GCT provides a transparent framework for estimating end-to-end costs (from sample collection to data analysis) helping countries and global partners make evidence-based investments in sustainable genomic surveillance systems. Support manufacturers quality standards in Indonesia: Through supporting manufacturer quality standards in Indonesia, FIND provided technical assistance to Indonesian IVD manufacturers to strengthen the quality of locally made diagnostic products for primary healthcare. Activities included training, quality system assessments, and support for regulatory compliance to enhance local manufacturing capabilities. Develop interoperability standards for One Health and newly procured diagnostics to ensure data can inform public-health decision making in Indonesia: FIND developed interoperability standards for One Health and new diagnostics to ensure that data generated from human, animal, and environmental health sources could be integrated and used to inform public health decision-making. This project supported the development of a unified digital health ecosystem. Ensuring equitable access to AI-powered diagnostics in low- and middle-income countries: Equitable access to AI-based diagnostic innovation was advanced in India, Indonesia, and Rwanda through the co-creation of a toolkit for innovating and scaling AI-based diagnostics with partners (e.g., C4IR, Indonesia MoH, and Artpark). The toolkit was applied and tested in in-country workshops to refine its effectiveness in evaluating AI diagnostics and building optimization capacity.Self-testing as a new critical tool to increase access to diagnostics for HIV, hepatitis B, and C virus infections Funded by the NIH, FIND's self-testing initiative advanced the evaluation
- $5.2 million spent. (EXPENSES $5,232,718 INCLUDING GRANTS OF $422,632)(REVENUE $0) In 2024, the FIND Access Department advanced its mission to ensure equitable access to quality diagnostics through strategic initiatives across multiple countries. Our work was organized around four key pillars: Laboratory System Strengthening, Diagnostic Network Optimization (DNO), Non-Communicable Diseases (NCDs), and Training & Capacity Building. This report summarizes the progress and achievements within these thematic areas throughout the year. Laboratory System Strengthening FIND enhanced the quality and sustainability of laboratory services through direct technical assistance. In Bihar, India, the Laboratory System Strengthening project provided support across all 38 districts, mentoring Medical Colleges and implementing quality management systems. This included training over 1,300 staff and conducting 350 site visits, which significantly increased the availability of diagnostic tests. In Indonesia, FIND assisted three referral laboratories in preparing for ISO 15189 accreditation and also led the coordination of the National EDL (NEDL) development in collaboration with the Ministry of Health and other stakeholders. This involved extensive stakeholder engagement and technical working group sessions with relevant Ministry directorates and subject matter experts, contributing to the broader ASEAN Diagnostic Security and Self-Reliance framework. In Bangladesh, technical assistance strengthened TB lab services through SLMTA mentoring at six reference labs, the introduction of a new Laboratory Information Management System, and building national capacity for quality assurance. Diagnostic Network Optimization (DNO) Using geospatial analysis and evidence-based modeling, FIND supported governments in rationalizing diagnostic networks for improved efficiency and access. In Indonesia, the DNO initiative focused on optimizing the TB diagnostic network by identifying optimal platform placement and streamlining sample pathways. In Bangladesh, the project mapped facilities and modeled optimized configurations for TB, HIV, and Malaria services to inform the upcoming National Strategic Plan. In Lao PDR, technical assistance was provided began to develop a national operational plan for an integrated sample transportation system. Globally FIND developed and piloted DxPulse, a new open-source diagnostic network visualization and analysis tool integrated within DHIS2. The pilot in Kenya in 2024, involving two counties, demonstrated its potential for improving data-driven planning and monitoring of diagnostic networks. Non-Communicable Diseases (NCDs) FIND expanded its focus on NCDs by generating critical evidence for policy and investment. The ACCEDE project in South Africa and Kenya, an operational research initiative, is building a local investment case for equitable adoption of continuous glucose monitoring (CGM) in public health systems. The project, co-created with Ministries of Health, combines clinical research and health economic modeling. It also includes a strong capacity-building component, having trained over 670 healthcare professionals across both countries through online and in-person sessions. Training and Capacity Building Building human resource capacity was a key cross-cutting theme. FIND expanded its online training portfolio through the FIND Training Academy. Courses launched in 2024 included "Introduction to Diagnostic Network Optimization (DNO) 2.0," "Introduction to Next-Generation Sequencing and Bioinformatics (INSEQBIN), "Online Training for AMR Scorecard Assessors." The DNO 2.0 course, developed with WHO SERAO, IDC, and ASLM, enrolled 321 learners from 71 countries, while the INSEQBIN course, in partnership with Fondation Merieux, trained 114 learners from 26 countries. In Indonesia, FIND also developed the "Fundamental Training on Essential Diagnostics" curriculum for the Ministry of Health to enhance laboratory workforce capacity in implementing new diagnostic tools and referral systems.
- $4.9 million spent. (EXPENSES $4,890,020 INCLUDING GRANTS OF $627,673) (REVENUE $0) TB Programme Activities - 2024 Summary 1. TB Fluorescent LAM Test Development This project focused on advancing fluorescent-based LAM assays to improve diagnostic sensitivity for TB in HIV-positive populations. In 2024, prototype assays were refined and evaluated in controlled laboratory settings. Preliminary data demonstrated enhanced detection rates compared to conventional LAM tests, paving the way for field validation. 2. TPP for Centralised TB Assays The initiative aimed to develop Target Product Profiles (TPPs) for centralised TB diagnostic platforms to guide manufacturers and procurement agencies. During 2024, consensus workshops were held with global stakeholders to finalise specifications for accuracy, throughput, and cost-effectiveness. The resulting TPPs were published and disseminated to inform future product development. 3. TB-CAPT (Close the gap, increase Access, Provide adequate Therapy) TB-CAPT sought to expand access to TB diagnosis and treatment in high-burden countries through integrated service delivery. In 2024, the programme scaled up TB testing and primary health centres and improved linkage-to-care pathways in multiple regions. These efforts resulted in thousands of additional patients initiating timely therapy. Three separate trials were conducted to increase access and diagnosis in symptomatic adults, PLHIV and people with drug-resistant TB. These studies have lead to policy changes and adoption in countries. 4. Predicting the Future: Incipient Tuberculosis (PreFIT) PreFIT aimed to identify biomarkers and predictive models for incipient TB to enable early intervention. Over the year, large cohort studies in South Africa, Mozambique and Uganda were initiated and data analysis frameworks established. Multiple novel tests were evaluated for performance in diagnosing active TB and predicting progression to TB. The primary test evaluated was Cepheid's Xpert Host Response transcriptomic test. 5. Bioneer Accupower RFIA Clinical Evaluation This project evaluated the laboratory analytical and clinical performance of the Bioneer Accupower Rapid Fluorescent Immunoassay for TB detection. In 2024, multi-site trials were completed across diverse epidemiological settings in Peru, Kenya and Ukraine. Specimens have been banked, and a new version of the test will be released in 2025 to complement results. This data will be used to support regulatory submission plans in 2026. 6. FEND for TB (Feasibility of Novel Diagnostics for TB in Endemic Countries) FEND for TB assessed the operational feasibility of introducing novel TB diagnostics in resource-limited settings. During 2024, pilot deployments were conducted in endemic countries, focusing on performance and accuracy of prototype early-stage diagnostics. Over 300 products were assessed through scouting, and over 60 products entered into evaluations in the lab and/or clinic across 5 countries. 7. Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) The R2D2 TB Network aimed to accelerate collaborative research on innovative TB diagnostics. In 2024, the network expanded to include new academic and industry partners and launched joint studies on next-generation assays. These collaborations produced early prototypes and shared data platforms to speed development. FIND supported scouting activities, data coordination for trialing and evidence generation, shared manuscript, and chest xray evaluations. 8. TB Triage Test This project focused on evaluating triage tests for TB to optimise patient flow in primary care settings. In 2024, field studies assessed performance in high-volume clinics and explored integration with digital tools. Results showed improved case detection and reduced diagnostic delays.Primary assays evaluated were the blood-based MBT host proteomic biomarker assay, and the Xpert HR cartrridge. 9. UNITE4TB (Academia and Industry United Innovation and Treatment for TB) UNITE4TB advanced partnerships between academia and industry to accelerate TB treatment innovation. In 2024, the consortium initiated clinical trials for novel drug regimens and strengthened regulatory engagement. These efforts positioned the programme as a key contributor to global treatment pipeline development. FIND's role has been to ensure that diagnostics development keeps pace with drug regimen approvals so that the appropriate tests are available to detect resistance before it emerges. 10. Drive Diagnostics for Tuberculosis The DriveDx4TB project aimed to fast-track deployment of diagnostic platforms in priority geographies. In 2024, procurement frameworks were established and training delivered to local laboratories. This resulted in expanded diagnostic coverage and improved turnaround times for TB testing. 11. Truenat COMBO: Bidirectional Dx for TB and Covid-19, with extensive tongue swab banking COMBO integrated multiplex molecular diagnostics for TB and COVID-19 while creating a biobank of tongue swab samples. In 2024, dual testing protocols were validated and implemented in pilot sites. The biobank now supports ongoing research into non-invasive sampling methods. 12. Optimise Xpert oriented Active Case finding for TB and COVID-19 (XACT-19) XACT-19 focused on optimising active case finding strategies using Xpert platforms for TB and COVID-19. In 2024, community screening campaigns were expanded and operational workflows streamlined. These interventions significantly increased detection rates for both diseases. 13. Next-generation TB LAM Tests This project supported the development of ultra-sensitive LAM assays for TB diagnosis in vulnerable populations. In 2024, candidate tests progressed through analytical validation and early clinical evaluation. Data indicated substantial improvements in sensitivity compared to existing LAM tests. 14. TB Lab Development and Support (India) The programme aimed to strengthen TB laboratory capacity through infrastructure and te
- $22.1 million spent. Neglected Tropical Diseases (Expenses $4,890,019) NT-P19-003 Chagas Diagnostics Market Sizing Model NT-P16-001 HAT diagnostic algorithm for South Sudan NT-P18-002 INtermediary field evalution report including the RDT performance against the reference standard NT-P19-003 Market Landscape Report of Diagnostic Products for Chagas Disease NT-P18-002 Report detailing the economic analysis of using the SCH CAA RDT instead of current diagnostic tools NT-P16-001 South Sudan HAT Access Database NT-P23-004 Test Directory for Visceral Leishmaniosis Medical Affairs Department (Expenses $4,108,156) Administrative clinical activities Womens Health Department (Expenses $3,248,296) WH-P23-001 Advancing Self collection for HPV testing as a primary cervical cancer screening strategy in sub-saharan Africa WH-P23-001 Assessing feasibility and effectiveness of point-of-care limited HPV genotype tests in cervical cancer screening: a modelling study WH-P23-001 Assessing Feasibility and efficiency of limited HPV genotype targets in cervical cancer screening for sub-saharan Africa WH-P23-001 Human Papillomavirus self-sampling versus provider-sampling in LMIC countries WH-P24-001 Technology Landscape of tools for Anaemia at Primary Health Centers WH-P23-001 Towards 70% cervical cancer screening coverage WH-P23-001 TPPs and relevance of community engagement Pandemic Threats (Expenses $3,232,156) PT-P24-003 Chikungunya test directory PT-P22-006 Diagnostic Accuracy of Three Mpox Lateral Flow Assays for Antigen Detection in the Democratic Republic of Congo and the United Kingdom PT-P22-005 DNO Analysis for Lassa and Yelloe fever in Nigeria PT-P24-002 DxConnect test directory for Lassa PT-P24-002 DxConnect test directory for Nipah PT-P22-006 Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab sa PT-P24-001 Filovirus Landscape PT-P23-002 i-MCM-Net Mapping Document PT-P24-002 Lassa landscape Manuscript PT-P21-001 License Agreement for Yellow Fever Ag NS1 RDT PT-P24-004 Mpox test directory PT-P24-004 Mpox test tracker PT-P23-002 PDxRI PT-P22-007 Viral Hemorrhagic Fever Strategic Plan PT-P23-002 WHS Roadmap for 100DM for Diagnostics meeting report Antimicrobial Resistance (Expenses $2,773,685) AM-P22-002 A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries FE-P18-003 A Qualitative Thematic Synthesis Study with a discussion of Intervention Design to explore drivers of adherence to prescription in four sites in India AM-P21-001 Affordable blood culture systems from China: in vitro evaluation for use in resource-limited settings AM-P24-001 Antimicrobial Stewardship Modules AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 30 health facilities in India AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 10 Counties in Kenya AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in Kenya AM-P21-001 Blood culture bottles remain efficient months after their expiration date: Implications for low- and middle-income countries. AM-P22-002 Call for public consultation: Target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final TPP currently in clearance) FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa AM-P22-003 Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of Neisseria gonorrhoeae at the Point of Care AM-P22-003 Evaluation of a novel point-of-care lateral flow assay screening for Neisseria gonorrhoeae infection among pregnant women in Zimbabwe AM-P24-001 Guidelines on Prudent Use of Antimicrobials in Animals FE-P18-003 Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in B AM-P22-003 Implementation considerations for a point-of-care Neisseria gonorrhoeae rapid diagnostic test at primary healthcare level in South Africa: a qualitative study AM-P23-006 Investment case for the use of diagnostics for enhancing STI management in South Africa AM-P23-006 Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings AM-P22-002 Multicentre external validation of the Neonatal Healthcare-associated infectiOn Prediction (NeoHoP) score: a retrospective case-control study AM-P24-001 National AMR Surveillance Report AM-P22-003 Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation AM-P23-006 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-002 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-004 Progress made in digitalizing antimicrobial resistance surveillance in a One Health approach in Kenya AM-P21-001 Rapid bacterial identification and resistance detection in positive blood cultures from patients with sepsis in Harare, Zimbabwe: evaluation of a low complexity molecular diagnostic platform AM-P22-003 Usability of a novel lateral flow assay for the point-of-care detection of Neiss
- (Expenses $ 22,071,233 including grants of $ 5,130,626)(Revenue $ 0) Neglected Tropical Diseases (Expenses $4,890,019) NT-P19-003 Chagas Diagnostics Market Sizing Model NT-P16-001 HAT diagnostic algorithm for South Sudan NT-P18-002 INtermediary field evalution report including the RDT performance against the reference standard NT-P19-003 Market Landscape Report of Diagnostic Products for Chagas Disease NT-P18-002 Report detailing the economic analysis of using the SCH CAA RDT instead of current diagnostic tools NT-P16-001 South Sudan HAT Access Database NT-P23-004 Test Directory for Visceral Leishmaniosis Medical Affairs Department (Expenses $4,108,156) Administrative clinical activities Womens Health Department (Expenses $3,248,296) WH-P23-001 Advancing Self collection for HPV testing as a primary cervical cancer screening strategy in sub-saharan Africa WH-P23-001 Assessing feasibility and effectiveness of point-of-care limited HPV genotype tests in cervical cancer screening: a modelling study WH-P23-001 Assessing Feasibility and efficiency of limited HPV genotype targets in cervical cancer screening for sub-saharan Africa WH-P23-001 Human Papillomavirus self-sampling versus provider-sampling in LMIC countries WH-P24-001 Technology Landscape of tools for Anaemia at Primary Health Centers WH-P23-001 Towards 70% cervical cancer screening coverage WH-P23-001 TPPs and relevance of community engagement Pandemic Threats (Expenses $3,232,156) PT-P24-003 Chikungunya test directory PT-P22-006 Diagnostic Accuracy of Three Mpox Lateral Flow Assays for Antigen Detection in the Democratic Republic of Congo and the United Kingdom PT-P22-005 DNO Analysis for Lassa and Yelloe fever in Nigeria PT-P24-002 DxConnect test directory for Lassa PT-P24-002 DxConnect test directory for Nipah PT-P22-006 Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab sa PT-P24-001 Filovirus Landscape PT-P23-002 i-MCM-Net Mapping Document PT-P24-002 Lassa landscape Manuscript PT-P21-001 License Agreement for Yellow Fever Ag NS1 RDT PT-P24-004 Mpox test directory PT-P24-004 Mpox test tracker PT-P23-002 PDxRI PT-P22-007 Viral Hemorrhagic Fever Strategic Plan PT-P23-002 WHS Roadmap for 100DM for Diagnostics meeting report Antimicrobial Resistance (Expenses $2,773,685) AM-P22-002 A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries FE-P18-003 A Qualitative Thematic Synthesis Study with a discussion of Intervention Design to explore drivers of adherence to prescription in four sites in India AM-P21-001 Affordable blood culture systems from China: in vitro evaluation for use in resource-limited settings AM-P24-001 Antimicrobial Stewardship Modules AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 30 health facilities in India AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 10 Counties in Kenya AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in Kenya AM-P21-001 Blood culture bottles remain efficient months after their expiration date: Implications for low- and middle-income countries. AM-P22-002 Call for public consultation: Target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final TPP currently in clearance) FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa AM-P22-003 Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of Neisseria gonorrhoeae at the Point of Care AM-P22-003 Evaluation of a novel point-of-care lateral flow assay screening for Neisseria gonorrhoeae infection among pregnant women in Zimbabwe AM-P24-001 Guidelines on Prudent Use of Antimicrobials in Animals FE-P18-003 Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in B AM-P22-003 Implementation considerations for a point-of-care Neisseria gonorrhoeae rapid diagnostic test at primary healthcare level in South Africa: a qualitative study AM-P23-006 Investment case for the use of diagnostics for enhancing STI management in South Africa AM-P23-006 Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings AM-P22-002 Multicentre external validation of the Neonatal Healthcare-associated infectiOn Prediction (NeoHoP) score: a retrospective case-control study AM-P24-001 National AMR Surveillance Report AM-P22-003 Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation AM-P23-006 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-002 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-004 Progress made in digitalizing antimicrobial resistance surveillance in a One Health approach in Kenya AM-P21-001 Rapid bacterial identification and resistance detection in positive blood cultures from patients with sepsis in Harare, Zimbabwe: evaluation of a low complexity molecular diagnostic platform AM-P22-003 Usability o
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated September 30, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated September 10, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2024.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since October 2003.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 7, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.